Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate.

Porter, Ross J et al.·The journal of pathology. Clinical research·2021·
RPEP-056922021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate.
Published In:
The journal of pathology. Clinical research, 7(5), 495-506 (2021)
Database ID:
RPEP-05692

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-05692·https://rethinkpeptides.com/research/RPEP-05692

APA

Porter, Ross J; Murray, Graeme I; Alnabulsi, Abdo; Humphries, Matthew P; James, Jacqueline A; Salto-Tellez, Manuel; Craig, Stephanie G; Wang, Ji M; Yoshimura, Teizo; McLean, Mairi H. (2021). Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate.. The journal of pathology. Clinical research, 7(5), 495-506. https://doi.org/10.1002/cjp2.222

MLA

Porter, Ross J, et al. "Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate.." The journal of pathology. Clinical research, 2021. https://doi.org/10.1002/cjp2.222

RethinkPeptides

RethinkPeptides Research Database. "Colonic epithelial cathelicidin (LL-37) expression intensity..." RPEP-05692. Retrieved from https://rethinkpeptides.com/research/porter-2021-colonic-epithelial-cathelicidin-ll37

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.